论文部分内容阅读
中国科学报讯中科院上海药物所耿美玉课题组和丁健院士课题组合作,研究揭示了组蛋白去乙酰化酶(HDAC)抑制剂对乳腺癌治疗不敏感的机制。相关研究已在线发表于《癌症细胞》。HDAC抑制剂是靶向肿瘤表观遗传修饰的分子靶向药物,但其治疗实体肿瘤效果不佳,且因机制不明,尚无合理的用药策略,极大限制其在临床上的广泛使用,成为领域内亟待解决的科学问题。该研究以乳腺癌/三阴乳腺癌为切入点,首次揭示细胞因子受体家族成员白血病抑制因子受体(LIFR)的反馈激活,是介导
China Science Bulletin Geng Meiyu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Working Group and Dr. Ding Jian, research revealed that histone deacetylase (HDAC) inhibitors are not sensitive to breast cancer treatment mechanism. Related research has been published online in “Cancer Cells.” HDAC inhibitor is a molecular targeted drug targeting epigenetic modification of tumor. However, its efficacy in treating solid tumor is poor. Because of its unclear mechanism, there is no reasonable strategy for HDAC inhibitor, which greatly limits its wide use in clinic and becomes Scientific problems to be solved in the field. The study of breast cancer / triple-negative breast cancer as a starting point for the first time reveals a member of the cytokine receptor leukemia inhibitory factor receptor (LIFR) feedback activation is mediated